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Dietary interventionLow-density lipoprotein (LDL) cholesterol lowering efficacy of a new type of chewable plant stanol ester
food supplement was evaluated in a randomized, double-blind, controlled four-week intervention. The
participants (LDL cholesterol > 3 mmol/L) consumed four supplements daily with meals either with
(n = 50) or without (n = 53) plant stanol esters. Plant stanol ester supplement (2 g/d plant stanols) low-
ered LDL cholesterol by 7.6%, serum cholesterol by 4.9%, and non-high density lipoprotein (HDL) choles-
terol by 6.6% compared with controls (P < 0.003). HDL cholesterol or serum triacylglycerol concentrations
were unchanged. The taste of the supplement was considered good/very good by 68% of the responders,
and convenience to consume it was considered easy/very easy by 78% of the responders. No side effects
were reported.
In conclusion, this new type of small-volume chewable plant stanol ester supplement lowered LDL
cholesterol concentration in hypercholesterolemic subjects providing a convenient dietary tool to regu-
late circulating cholesterol levels.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Modification of diet is an essential approach for the manage-
ment of elevated low density lipoprotein (LDL) cholesterol concen-
tration either alone or alongside with lipid lowering medication.
The efficacy of plant stanol esters administered in foods especially
in spreads and yoghurt drinks is established to lower LDL choles-
terol concentration by 9–10% at a daily dose of 2 g plant stanols
(Demonty et al., 2009; Musa-Veloso, Poon, Elliot, & Chung, 2011;
Ras, Geleijnse, & Trautwein, 2014). This amount of LDL cholesterol
reduction is clinically relevant, since it is estimated that for every
1% reduction in LDL cholesterol concentration there is a corre-
sponding 1% decrease in the risk of coronary artery disease
(LaRosa, 2007).
There is a need for new dietary tools that are, in addition to hav-
ing proven efficacy, convenient to use daily. Plant stanols inhibit
cholesterol absorption by displacing cholesterol from mixed
micelles in the proximal intestine so that less cholesterol is trans-ported from the intestine to the liver (Armstrong & Carey, 1987;
Ikeda, Tanaka, Sugano, Vahouny, & Gallo, 1988; Miettinen,
Vuoristo, Nissinen, Järvinen, & Gylling, 2000; Racette et al., 2010).
The whole process is complicated and vulnerable to disturbances.
It is even possible that no LDL cholesterol lowering occurs
(Davidson et al., 2001; Denke, 1995; Ottestad et al., 2013). Conse-
quently, when plant stanol esters are added to a novel type of food
matrix, even the structure and volume of the product matrix has an
impact on the success of cholesterol absorption inhibition, and the
functionality of new types of products should be confirmed with
clinical studies. It is noteworthy that most of the studies included
in the large meta-analyses and to which the LDL cholesterol lower-
ing efficacy of plant stanol ester food products is based are per-
formed with plant stanols/sterols added to solid foods or large-
volume yoghurts and drinks. Regarding small-volume products,
there is recent evidence that softgel capsules with added plant sta-
nols/sterols have substantial variation in their LDL cholesterol low-
ering efficacy. In the five published studies, plant stanol/sterol
softgel capsules had either no effect (Ottestad et al., 2013) or they
reduced the placebo-corrected LDL cholesterol concentration from
4% to 9% (Maki et al., 2012; Maki et al., 2013; McKenney et al.,
2014; Woodgate, Chan, & Conquer, 2006). The doses of added plant
stanols or plant sterols did not explain the conflicting results,
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in the four positive studies (1.6 or 1.8 g/day).
In this study, a new type of plant stanol ester food supplement
was developed. Its matrix is structurally completely different from
commercially available plant stanol or plant sterol supplements
such as softgel capsules or tablets (e.g., Maki et al., 2012; Maki
et al., 2013; McKenney et al., 2014; Ottestad et al., 2013;
Woodgate et al., 2006). This small-volume low-fat chewable and
easy to swallow food supplement is based on emulsified plant sta-
nol esters in a gelled water phase in order to ensure effective
release of the emulsified plant stanol esters from the product
matrix in the stomach. To this end, the aim of this study was to
investigate the LDL cholesterol lowering efficacy of this new plant
stanol ester dietary supplement in a four-week randomized,




A total of 131 volunteers were recruited from the Helsinki city
area through advertisements in a local newspaper, on notice
boards in Helsinki University Central Hospital, and also through
contacting potentially eligible study participants from our earlier
studies (Fig. 1). The study was conducted at Helsinki University
Central Hospital, Helsinki, Finland. The inclusion criteria were:
men and women over 18 years of age, LDL cholesterol concentra-
tion > 3 mmol/L, and body mass index (BMI) < 35 kg/m2. Exclusion
criteria were: kidney, liver, or thyroid malfunction, inflammatoryAssessed for elig
Analysed  (n=50)
♦ Excluded from analysis (discontinued 
intervention) (n=5)
Lost to follow-up (n=0)
Discontinued intervention (gastrointestinal 
discomfort, n=1, headache, n=1, personal 
reasons, n=3), (n=5) 
Allocated to intervention, plant stanol group
(n=55) 
♦ Received allocated intervention (n=55)






Fig. 1. Flow chartbowel disease, unstable chronic disease such as coronary heart dis-
ease or coronary procedure within six months, lipid-lowering med-
ication, or the consumption of nutrient supplements interfering
with serum cholesterol level (red rice or berberine), gravidity or
breast feeding, allergy or hypersensitivity to any component of
the test product, alcohol consumption > 45 g absolute alcohol/day,
or participating simultaneously in another clinical trial. If the sub-
jects had used plant stanol/sterol products, they could be included
in the study after a two weeks’ wash out period.
All subjects gave their written informed consent prior to the
inclusion in the study. The study was performed according to the
principles of the 1964 Declaration of Helsinki and its later amend-
ments. The Ethics Committee of theDepartment ofMedicine, Hospi-
talDistrictofHelsinki andUusimaahadapproved the studyprotocol.
The trial was registered at ClinicalTrial.gov (NCT02221297).
2.2. Study design
The study was a randomized, controlled, double-blind and par-
allel clinical trial with an intervention phase of four weeks. The
subjects were divided into plant stanol and control groups. Ran-
domization was executed in blocks of 10 subjects using an
Internet- based program by the manufacturer of the supplement
who also kept the code sealed until the last study visit. Enrolment
of the participants was performed continuously according to a ran-
domization list with three digit random numbers thus both the
researchers and study participants were blind to the study code.
The subjects attended a screening visit before randomization and
two visits after enrolment, one at baseline and one at the end of
the intervention. During the visits, fasting blood samples wereibility (n=131)
Excluded (n=21) 
♦ Not meeting inclusion criteria  (n=8) 
♦ Declined to participate (n=7) 
♦ Other reasons (n= 6) 
Lost to follow-up (n=0)
Discontinued intervention (migraine, n=1, 
personal reasons, n=1), (n=2) 
Allocated to intervention, control group (n=55)
♦ Received allocated intervention (n=55)
♦ Did not receive allocated intervention (n=0)
Analysed  (n=53)
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ference (at baseline), and blood pressure (at baseline) were mea-
sured. The subjects were requested not to alter their lifestyle
habits including diet and exercise during the study. Possible con-
comitant medication should have remained unchanged for
1 month before the study and, if possible, during the study.
The primary outcome was the proportional change in LDL
cholesterol concentration (end of intervention minus baseline)
between the study groups in subjects completing the study. Sec-
ondary outcomes were the proportional change in the serum total
cholesterol, non-high density lipoprotein (HDL) cholesterol, HDL
cholesterol, and serum triacylglycerol concentrations between
the study groups in subjects completing the study.
2.3. Test products
The participants were advised to consume four pieces of the test
supplements (Raisio Nutrition Ltd., Raisio, Finland) daily with
meals in two daily lots for four weeks. The supplements were
chewable in consistency and did not require water for consump-
tion. The daily dose of plant stanols was 2 g. The supplement was
sugar free and sweetened with xylitol and flavored with lemon
and lime. The nutritional composition of the supplements is pre-
sented in Table 1. The supplements were packed in aluminium
blisters that could be stored at room temperature. The supple-
ments with and without plant stanol ester were packed in identical
blisters and cardboard packages, which were labeled with individ-
ual three digit random numbers according to the randomization
list. Thus, in the parallel study design, the intervention and placebo
product could not be identified by the participants or the research-
ers executing the study, despite the slight difference in consistency
of the two test products.
2.4. Compliance
Participants kept a diary daily on the intake of the study prod-
ucts and on any potential symptoms experienced during the con-
sumption of the products. The participants were asked to return
all blisters at the last study visit. The compliance was calculated
as a proportion of the number of the consumed supplements
(empty blisters) from the number of the prescribed supplements
for the four-week intervention period. The participants filled in a
questionnaire relating to sensory properties and experiences on
using the supplement.
2.5. Dietary intake
Dietary intake was assessed prior to the baseline and the last
study visit with 3-day food diaries covering 2 day during the week
and 1 day on the weekend. The mean daily intakes of energy and
nutrients were calculated using computerized dietary analysis pro-
gram (AivoDiet, Aivo Finland Ltd., Turku, Finland).Table 1
Nutritional composition of the intervention supplements.
Nutrition values 4 pieces Plant stanol ester
supplement
Control
supplement(6.7 g), daily portion
Energy (kJ) 80 100
Total fat (g) 1.5 1.6
of which - saturated (g) 0.1 0.1
Total carbohydrates (g) 1.6 3.1
of which - sugars (g) 0.0 0.0
- polyols (g) 1.3 3.1
Total protein (g) 0.3 0.4
Plant stanols (g) 2.0 0.02.6. Blood sampling and analyses
Fasting blood samples were drawn from the antecubital vein
after 12-hours’ fasting. The subjects were advised to avoid heavy
exercise and not to drink alcohol on the preceding day. Serum total,
HDL cholesterol, serum triacylglycerols, and plasma glucose were
determined enzymatically using automated analyzers with stan-
dardized methods at the certified Central Laboratory of Helsinki
University Hospital (HUSLAB). LDL cholesterol was calculated
using Friedewald’s equation, and the results were checked with
the enzymatic analysis at HUSLAB. Non-HDL cholesterol was calcu-
lated as follows: non-HDL cholesterol = total cholesterol  HDL
cholesterol.2.7. Statistical analyses
Statistical analyses were performed with SPSS for Windows
19.0 statistics program (SPSS, Chicago, IL, USA). The number of sub-
jects recruited was based on a power analysis to detect a 10% dif-
ference in LDL cholesterol response between the study groups with
an a level of 0.05 and with statistical power of 0.80. The normality
and homogeneity of variance assumptions were checked before
further analyses, and all variables were normally distributed. The
comparisons between the plant stanol and control groups were
tested using independent samples t-test. Non-continuous variables
were tested with chi-square or Fisher’s exact test. A P-value of
<0.05 was considered statistically significant. The results are given
as mean ± SE.3. Results
3.1. Demographics and clinical characteristics at baseline and after
intervention
Of the 110 subjects randomized to the intervention, five sub-
jects dropped out from the plant stanol group, one because of
headache and one for gastrointestinal discomfort, and three for
personal reasons (Fig. 1). Two subjects dropped out from the con-
trol group, one because of migraine and one for personal reasons.
Accordingly, 103 subjects, 50 in the plant stanol and 53 in the
control group completed the study and were included in the
analyses.
The main clinical characteristics of the study population are
demonstrated in Table 2. Age varied from 27 to 84 years with a
mean value of 60 ± 1 (SE) years in the whole study population,
and LDL cholesterol concentration varied from 3.08 to
6.69 mmol/L with a mean value of 4.1 ± 0.1 mmol/L, respectively.
Seven subjects had elevated serum triacylglycerol concentration
varying from 2.01 to 3.29 mmol/L. All subjects with a history of
hypothyreosis were on adequate medication. The two subjects
with type 2 diabetes in the control group were on oral hypo-
glycemic treatment with good glycemic control and without com-
plications. The gender distribution, demographics, clinical
characteristics including prevalence of diseases and different
types of medication, and serum and lipoprotein cholesterol con-
centrations at baseline did not differ between the groups (Tables
2 and 3). The only exceptions were the slightly higher plasma
glucose concentration in the control than in the plant stanol
group because of the two diabetics present in the control group,
and serum triacylglycerol concentration was higher in the control
than in the plant stanol group. The mean plasma glucose and
serum triacylglycerol concentrations were, however, within the
general reference values in both groups (plasma glu-
cose < 6.0 mmol/L, serum triacylglycerol 6 1.70 mmol/L). More-
over, the higher plasma glucose and serum triacylglycerol
Table 2
Baseline characteristics.
Variables Plant stanol ester group
(n = 50)
Control group (n = 53) Pa,b
Gender (M/F), n 11/39 15/38 0.462
Age (y) 59.6 (±1.4) 60.1 (±1.4) 0.812
Weight (kg) 75.7 (±1.8) 73.4 (±1.6) 0.329
Body mass index (kg/m2) 26.4 (±0.5) 26.0 (±0.5) 0.607
Waist circumference (cm) 93.6 (±1.4) 92.5 (±1.4) 0.567
Plasma glucose (mmol/L) 5.3 (±0.6) 5.7 (±0.9) 0.020
Diseases, n
Hypertension 9 15 0.216
Hypothyreosis 5 10 0.202
Asthma bronchiale 2 8 0.057
Diabetes mellitus, type 2 0 2 0.165
Atrial fibrillation 2 0 0.141
Medication, n
Angiotensin receptor blockers or angiotensin converting enzyme inhibitors 6 7 0.854
Diuretics 4 3 0.637
Beta blockers 1 6 0.060
Calcium channel blockers 1 4 0.190
Thyroxin 5 10 0.202
Contraceptives or hormone replacement therapy 5 4 0.660
Mean (± SE).
a Independent samples t-test.
b chi-square or Fisher’s exact test.
Table 3
Serum and lipoprotein lipids (mmol/L) at baseline and after 4 weeks’ intervention and change (mmol/L) from baseline.
Variables Plant stanol ester group,
n = 50
Control group, n = 53 Mean difference in
response
Pa
Mean (SE) Mean (SE) Mean (SE)
LDL cholesterol
Baseline 4.05 (±0.10) 3.99 (±0.11) 0.700
After intervention 3.85 (±0.09) 4.10 (±0.12) 0.096
Change (mmol/L) 0.20 (±0.06) +0.11 (±0.07) 0.31 (±0.09) 0.001
Serum total cholesterol
Baseline 6.34 (±0.11) 6.38 (±0.11) 0.794
After intervention 6.18 (±0.10) 6.54 (±0.13) 0.030
Change (mmol/L) 0.16 (±0.07) +0.16 (±0.07) 0.32 (±0.10) 0.002
Non-HDL cholesterol
Baseline 4.53 (±0.11) 4.62 (±0.13) 0.580
After intervention 4.35 (±0.10) 4.75 (±0.14) 0.024
Change (mmol/L) 0.18 (±0.07) +0.13 (±0.07) 0.31 (±0.09) 0.001
HDL cholesterol
Baseline 1.81 (±0.07) 1.76 (±0.06) 0.580
After intervention 1.83 (±0.07) 1.79 (±0.07) 0.703
Change (mmol/L) +0.02 (±0.02) +0.03 (±0.03) 0.01 (±0.04) 0.706
Serum triacylglycerols
Baseline 1.07 (±0.06) 1.40 (±0.13) 0.018
After intervention 1.11 (±0.07) 1.44 (±0.12) 0.018
Change (mmol/L) +0.04 (±0.04) +0.04 (±0.06) 0.002 (±0.07) 0.982
a Between groups; independent samples t-test.
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was no sex difference in demographics, clinical characteristics, or
in serum and lipoprotein lipids in either of the study groups (NS
for all, data not shown).
At the end of the intervention, weight of the subjects was
unchanged (76.1 ± 1.8 kg, plant stanol ester group, and
73.5 ± 1.5 kg, control group, NS between the groups). The test
products were well tolerated, and no side effects were reported.
Based on calculating the returned supplements, 98% (74–107%) of
the supplements were consumed by the participants. The majority
considered the taste of the plant stanol ester supplement to be
good or very good (68% of the responders) and they also considered
the supplement to be easy or very easy to consume daily at the
advised dose for four weeks (78% of the responders).3.2. Serum and lipoprotein lipids
LDL cholesterol was reduced by 7.6% in the plant stanol group
compared to controls (P = 0.001) (Table 3). Serum total cholesterol
concentration was lowered by 4.9% and non-HDL cholesterol by
6.6% compared to controls (P < 0.003 for both). No statistically sig-
nificant change in HDL cholesterol (mean difference 0.01 mmol/
L) or serum triacylglycerols (mean difference 0.002 mmol/L) was
measured between the groups.
3.3. Dietary intake
At baseline and at the end of the study (Table 4), the dietary
intakes did not differ between the study groups. There was no sig-
Table 4
Dietary intake at the end of the intervention.
Variables Plant stanol ester group,
(n = 47)
Control group (n = 51) Mean difference Pa
Mean (SE) Mean (SE) Mean (SE)
Energy (MJ/d) 7.9 (±0.3) 7.9 (±0.3) +0.03 (±0.5) 0.952
Protein (% of energy) 17.9 (±0.4) 18.3 (±0.5) 0.4 (±0.7) 0.567
Carbohydrate (% of energy) 41.3 (±1.1) 39.3 (±0.9) +1.9 (±1.4) 0.173
Fat (% of energy) 36.1 (±0.9) 36.9 (±0.9) 0.8 (±1.2) 0.507
SFA (% of energy) 12.9 (±0.5) 12.5 (±0.4) +0.4 (±0.6) 0.520
MUFA (% of energy) 13.6 (±0.5) 13.7 (±0.5) 0.1 (±0.7) 0.887
PUFA (% of energy) 6.8 (±0.3) 6.7 (±0.3) +0.05 (±0.4) 0.912
Alcohol (% of energy) 1.8 (±0.5) 2.4 (±0.6) 0.5 (±0.8) 0.501
Cholesterol (mg/d) 240 (±23) 228 (±15) +12.1 (±27) 0.649
Fiber (g/d) 22.1 (±1.2) 22.9 (±1.2) 0.8 (±1.7) 0.621
a Independent samples t-test.
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the groups (NS for all, data not shown).4. Discussion
The novelty of this study was the effective LDL cholesterol low-
ering of a new type of a small-volume low-fat plant stanol ester
food supplement. In the moderately hypercholesterolemic study
population, LDL cholesterol concentration was significantly
reduced on average by 7.6% compared with controls, and the
respective significant reductions for serum total and non-HDL
cholesterol were 4.9% and 6.6%. As expected, HDL cholesterol and
serum triacylglycerol concentrations were unchanged. No side
effects were reported. Information was also gathered by the study
population related to the sensory properties and experiences on
using the supplement. The majority of the participants considered
this new type chewable supplement tasty and easy to consume
daily.
The design of the study was a randomized, double blind, con-
trolled clinical intervention, and according to the power calcula-
tion, the study population was large enough to adequately
address the research question. The randomization was successful
regarding gender, age, weight, BMI, distribution of diseases and
medication, and serum and lipoprotein cholesterol concentrations.
The higher plasma glucose and serum triacylglycerol values in the
control than in the plant stanol ester group did not affect the lipid
results.
In general, based on recent large meta-analyses (Demonty et al.,
2009; Musa-Veloso et al., 2011; Ras et al., 2014) it is considered
that plant stanols and plant sterols at the dose of 2 g/day lower
LDL cholesterol on average by 9–10%. Most of the studies included
in these analyses were randomized controlled trials and were per-
formed using solid food matrices with a markedly larger matrix
volume than is provided in the present study. At the moment there
is conflicting evidence of the efficacy of plant stanol or plant sterol
esters added in low-fat and small-size delivery forms of e.g., less
than 5 g such as softgel capsules (Maki et al., 2012; Maki et al.,
2013; McKenney et al., 2014; Ottestad et al., 2013; Woodgate
et al., 2006). In one of these studies the capsules had no LDL choles-
terol lowering effect (Ottestad et al., 2013), and in two studies the
efficacy was moderate, less than 5% (Maki et al., 2012; McKenney
et al., 2014). Accordingly, when new types of products with added
plant stanols/sterols are developed, their cholesterol-lowering effi-
cacy should be clinically evaluated.
In order to displace cholesterol from mixed micelles, plant sta-
nol esters must be hydrolysed in the upper part of the small intes-
tine. The first critical step in this process is a release of the plant
stanol ester from the food or food supplement matrix and mixing
it with the emulsified fat in the stomach. For effective hydrolysisof the plant stanol ester that is contained in the emulsified fat dro-
plets, the release of bile and pancreatic enzymes must be induced.
In the upper part of the small intestine pancreatic cholesterol
esterase hydrolyses the ester bonds of plant stanol esters to form
free plant stanols that displace cholesterol from the mixed
micelles. The amount of free plant stanols has to be large enough
for effective cholesterol displacement.
In the present chewable supplement the plant stanol esters
were emulsified in a gelled water matrix that release the emulsi-
fied plant stanol esters effectively in the stomach. The supplement
was consumed as part of a meal to ensure effective hydrolysis of
the plant stanol esters. Two recent studies demonstrate the impor-
tance of consuming plant stanol or plant sterol esters even in solid
food as biscuits or as a large single yoghurt drink of 100 g with a
meal (Doornbos, Meynen, Duchateau, van der Knaap, &
Trautwein, 2006; Kriengsinyos, Wangtong, & Komindr, 2015).
When plant stanol ester biscuits were consumed in-between
meals, LDL cholesterol concentration was practically unchanged,
whereas when consumed with a meal, LDL cholesterol concentra-
tion was significantly reduced compared to controls
(Kriengsinyos, Wangtong, & Komindr, 2015). The yoghurt drink
lowered LDL cholesterol concentration when taken without meal,
but the effect was significantly weaker compared to the same dose
consumed with a meal (Doornbos et al., 2006). Interestingly, in the
negative softgel capsule study (Ottestad et al., 2013) the unrespon-
siveness could not be explained by inadequate timing of consump-
tion, since the capsules were consumed with meals.
In conclusion, the present results demonstrated that plant sta-
nol esters in a new chewable small-volume low-fat format effec-
tively and without side-effects lowered LDL, serum total, and
non-HDL cholesterol concentrations without affecting HDL choles-
terol and serum triacylglycerol levels in a moderately hypercholes-
terolemic study population. The majority of the participants
considered the chewable supplement tasty and easy to consume
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